Small interfering RNA silencing of interleukin-6 in mesenchymal stromal cells inhibits multiple myeloma cell growth

Leukemia Research

Volumn 40, Issue , 2015, Pages 44-53

  Teoh, Hoon Koon ^a,b   Chong, Pei Pei ^b   Abdullah, Maha ^b   Sekawi, Zamberi ^b   Tan, Geok Chin ^a   Leong, Chooi Fun ^a   Cheong, Soon Keng ^a,c  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^b UPM   (Malaysia)

^c UNIVERSITI TUNKU ABDUL RAHMAN   (Malaysia)

Author keywords

Interleukin 6; Mesenchymal stromal cells; Multiple myeloma; RNA interference; SiRNA

Indexed keywords

5' NUCLEOTIDASE; CD34 ANTIGEN; CD45 ANTIGEN; HERMES ANTIGEN; INTERLEUKIN 6; SMALL INTERFERING RNA; THY 1 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CANCER GROWTH; CANCER INHIBITION; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR VOLUME; ANIMAL; CELL PROLIFERATION; COCULTURE; GENETICS; MESENCHYMAL STROMA CELL; PATHOLOGY; XENOGRAFT;

ANIMALS; CELL PROLIFERATION; COCULTURE TECHNIQUES; GENE SILENCING; HETEROGRAFTS; HUMANS; INTERLEUKIN-6; MESENCHYMAL STROMAL CELLS; MICE; MULTIPLE MYELOMA; RNA, SMALL INTERFERING;

EID: 84949032204     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.10.004     Document Type: Article

References (42)

1. Rajkumar S.V., Gertz M.A., Kyle R.A., Greipp P.R. Current therapy for multiple myeloma. Mayo Clin. Proc. 2002, 77:813-822.
2. Howlader N., Noone A.M., Krapcho M., Garshell J., Miller D., Altekruse S.F., et al. SEER Cancer Statistics Review, 1975-2011 2011, National Cancer Institute, Bethesda, MD, [cited 2014 29/12/2014]. http://seer.cancer.gov/csr/1975_2011/.
3. Ghia P., Granziero L., Chilosi M., Caligaris-Cappio F. Chronic B cell malignancies and bone marrow microenvironment. Semin. Cancer Biol. 2002, 12:149-155.
4. Kuehl W.M., Bergsagel P.L. Multiple myeloma: evolving genetic events and host interactions. Nat. Rev. Cancer 2002, 2:175-187.
5. Tosi P., Gamberi B., Giuliani N. Biology and treatment of multiple myeloma. Biol. Blood Marrow Transplant. 2006, 12:81-86.
6. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988, 332:83-85.
7. Anderson K.C., Jones R.M., Morimoto C., Leavitt P., Barut B.A. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989, 73:1915-1924.
8. Ogata A., Chauhan D., Teoh G., Treon S.P., Urashima M., Schlossman R.L., et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J. Immunol. 1997, 159:2212-2221.
9. Hideshima T., Anderson K.C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev. Cancer 2002, 2:927-937.
10. Lokhorst H.M., Lamme T., de Smet M., Klein S., de Weger R.A., van Oers R., et al. Primary tumour cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 1994, 84:2269-2277.
11. Sahara N., Takeshita A., Ono T., Sugimoto Y., Kobayashi M., Shigeno K., et al. Role for interleukin-6 and insulin-like growth factor-I via PI3-K/Akt pathway in the proliferation of CD56- and CD56+ multiple myeloma cells. Exp. Hematol. 2006, 34:736-744.
12. Corre J., Mahtouk K., Attal M., Gadelorge M., Huynh A., Fleury-Cappellesso S., et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007, 21:1079-1088.
13. Dankbar B., Padro T., Leo R., Feldmann B., Kropff M., Mesters R.M., et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000, 95:2630-2636.
14. Roodman G.D. Pathogenesis of myeloma bone disease. Blood Cells Mol. Dis. 2004, 32:290-292.
15. Klein B., Wijdenes J., Zhang X.G., Jourdan M., Boiron J.M., Brochier J., et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991, 78:1198-1204.
16. Bataille R., Barlogie B., Lu Z.Y., Rossi J.F., Lavabre-Bertrand T., Beck T., et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995, 86:685-691.
17. Moreau P., Harousseau J.L., Wijdenes J., Morineau N., Milpied N., Bataille R. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br. J. Haematol. 2000, 109:661-664.
18. van Zaanen H.C.T., Lokhorst H.M., Aarden L.A., Rensink H.J., Warnaar S.O., van der Lelie J., et al. Chimeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br. J. Haematol. 1998, 102:783-790.
19. Suzuki K., Ogura M., Abe Y., Suzuki T., Tobinai K., Ando K., et al. Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma. Int. J. Hematol. 2015, 101:286-294.
20. Caterson E.J., Nesti L.J., Danielson K.G., Tuan R.S. Human marrow-derived mesenchymal progenitor cells: isolation, culture expansion, and analysis of differentiation. Mol. Biotechnol. 2002, 20:245-256.
21. Sun S., Guo Z., Xiao X., Liu B., Liu X., Tang P.H., et al. Isolation of mouse marrow mesenchymal progenitors by a novel and reliable method. Stem Cells 2003, 21:527-535.
22. Freneaux P., Stoppa-Lyonnet D., Mouret E., Kambouchner M., Nicolas A., Zafrani B., et al. Low expression of bcl-2 in Brca1-associated breast cancers. Br. J. Cancer 2000, 83:1318-1322.
23. Sanceau J., Poupon M.F., Delattre O., Sastre-Garau X., Wietzerbin J. Strong inhibition of ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide. Oncogene 2002, 21:7700-7709.
24. Gao K., Huang L. Achieving efficient RNAi therapy: progress and challenges. Acta Pharm. Sin. B 2013, 3:213-225.
25. Merritt W.M., Lin Y.G., Spannuth W.A., Fletcher M.S., Kamat A.A., Han L.Y., et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J. Natl. Cancer Inst. 2008, 100:359-372.
26. McNamara J.O., Andrechek E.R., Wang Y., Viles K.D., Rempel R.E., Gilboa E., et al. Cell type-specific delivery of siRNAs with aptamer-siRNAs chimeras. Nat. Biotechnol. 2006, 24:1005-1015.
27. Masiero M., Nardo G., Indraccolo S., Favaro E. RNA interference: implications for cancer treatment. Mol. Aspects Med. 2007, 28:143-166.
28. Klein B., Zhang X.G., Jourdan M., Content J., Houssiau F., Aarden L., et al. Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. Blood 1989, 73:517-526.
29. Trikha M., Corringham R., Klein B., Rossi J.F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer Res. 2003, 9:4653-4665.
30. Ropponen K.M., Eskelinen M.J., Lipponen P.K., Alhava E., Kosma V.M. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J. Pathol. 1997, 182:318-324.
31. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348:203-213.
32. Marrogi A.J., Munshi A., Merogi A.J., Ohadike Y., El-Habashi A., Marrogi O.L., et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int. J. Cancer 1997, 74:492-501.
33. Simonson W.T.N., Allison K.H. Tumour-infiltrating lymphocytes in cancer: implications for the diagnostic pathologist. Diagn. Histopathol. 2010, 17:80-90.
34. Tamura H., Ishibashi M., Yamashita T., Tanosaki S., Okuyama N., Kondo A., et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 2013, 27:464-472.
35. Lu Z.Y., Brailly H., Wijdenes J., Bataille R., Rossi J.F., Klein B. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 1995, 86:3123-3131.
36. Chames P., Van Regenmortel M., Weiss E., Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol. 2009, 157:220-233.
37. Wang H., Lathia J.D., Wu Q.L., Wang J.L., Li Z.Z., Heddleston J.M., et al. Targeting interleukin-6 signalling suppresses glioma stem cell survival and tumor growth. Stem Cells 2009, 27:2393-2404.
38. Fulciniti M., Hideshima T., Vermot-Desroches C., Pozzi S., Nanjappa P., Shen Z.X., et al. A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of multiple myeloma. Clin. Cancer Res. 2009, 15:7144-7152.
39. Roccaro A.M., Sacco A., Thompson B., Leleu X., Azab A.K., Azab F., et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009, 113:6669-6680.
40. Wang J., Hendrix A., Hernot S., Lemaire M., De Bruyne E., Van Valckenborgh E., et al. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood 2014, 124:555-566.
41. Azmi A.S., Bao B., Sarkar F.H. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 2013, 32:623-642.
42. Roccaro A.M., Sacco A., Maiso P., Azab A.K., Tai Y.T., Reagan M., et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Invest. 2013, 123:1542-1555.